Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 12/20 | 0.48 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004710 | 0.87 | NPY2R (0.60) | NPY2R | |
| SCHEMBL18763033 | 0.80 | TGM2 (0.65) | GPR119F13A1TGM2TGM1 | |
| SCHEMBL5128217 | 0.79 | SHMT2 (0.53) | NPY2RSHMT2HTTNPSR1LMNA | |
| SCHEMBL4011718 | 0.78 | SHMT2 (0.49) | NPY2RSHMT2HTTNPSR1LMNA | |
| SCHEMBL17422197 | 0.77 | GPR119 (0.53) | GPR119F13A1TGM2TGM1DPP4 | |
| SCHEMBL6115001 | 0.77 | NPY2R (0.59) | NPY2RGPR119NPSR1 | |
| SCHEMBL2449157 | 0.76 | BACE1 (0.50) | GPR119 | |
| SCHEMBL24606792 | 0.76 | GPR119 (0.49) | GPR119DPP4LMNA | |
| SCHEMBL2445935 | 0.76 | GPR119 (0.49) | GPR119DPP4LMNA | |
| SCHEMBL18790571 | 0.76 | F13A1 (0.48) | GPR119F13A1TGM2TGM1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129870-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2009079597-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129870-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | NPY2R 1/4885SHMT2 4057/4885GPR119 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.